| |
| |
| Catalent Announces New Partnerships to Advance Cell and Gene Treatments |
|
|
|
|
| Catalent will support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies. CGMP manufacturing of the cell therapy will take place at Catalent’s facility in Gosselies, Belgium |
|
| | |
|
|
| |
| |
| |
| |
| |
| Catalent Launches CosmoPod® Duo New Dual Chamber Capsule for Beauty and Consumer Health Topical Applications |
|
|
|
|
| Based on Catalent’s established CosmoPod unit-dose twist-off capsule technology, the CosmoPod Duo capsule features segregated compartments to accommodate two formulations into a single twist-off capsule. The new dosing format allows for the simultaneous application of treatments that combine hero ingredients typically not compatible together; that have a shorter shelf life when combined; or two complementary hero ingredients. |
|
| | |
|
|
| |
| |
| Catalent is Proud to Support Many High-Profile COVID-19 Programs
Catalent has been awarded more than 80 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. |
|
|
|
|
| |
| |
| Catalent Announces Commercial Supply Agreement with Aurinia Pharmaceuticals for Newly-Approved LUPKYNIS™ Softgels
“Catalent has supported over 80% of all prescription pharmaceutical softgel brand launches in the U.S. It has nearly 90 years of experience in the formulation and manufacturing of softgels for both pharmaceutical and consumer health products, which it has drawn upon to jointly develop LUPKYNIS with Aurinia.” |
|
|
|
|
| |
| |
| Catalent Recognized as a Country Certified Top Employer 2021
Being certified as a Top Employer showcases an organization’s dedication to a better world of work and exhibits this through excellent HR policies and people practices. |
|
|
|
|
| |
| |
| Catalent Completes Acquisition of Dry Powder Inhaler Spray Drying, Capsule Manufacturing, and Packaging Capabilities from Acorda Therapeutics
“This acquisition complements our existing U.S.-based capabilities in metered-dose inhalers and nasal spray technologies by adding an experienced team of people and a premier facility enabling us to provide customers with extended capabilities for commercial- and clinical-scale spray drying, encapsulation and blister packaging of capsules for dry powder inhalers,” commented Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. |
|
|
|
|
| |
| |
| GPEx® Boost Shortlisted for The Medicine Maker’s Innovation Awards
GPEx Boost builds on Catalent’s proprietary GPEx technology with enhanced benefits, including up to four-fold higher titers in difficult-to-express proteins, reduced ammonia build-up to improve cell growth and viability, and fewer process steps. Vote for GPEx Boost. |
|
|
|
|
| |
| |
| Meeting Fill/Finish Challenges for COVID-19 Vaccines
Recently published in BioPharm International, Dhaval Patel, Senior Manager, Manufacturing Science & Technology, Catalent Biologics, discusses the challenges of liquid and lyophilized forms, and preparing for the large capacity needed for COVID-19 vaccines. |
|
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
|
|
|
| Biologics
Webinar | Early Phase Biologic Development: Upstream and Downstream Processes Considerations | February 23 Experts will discuss new cell line development methodologies which are enabling complex programs to be performed more efficiently, as well as ways that perfusion tools are used to implement upstream process intensification for clinical and commercial programs.
World ADC Europe 2021 | Virtual Conference | March 8 - 11 Penny Drake, Head of R&D, Bioconjugates, Catalent Biologics, will present “Catalent’s SMARTag ADC Technology: Differentiated Solutions for Optimal ADCs”.
BEBPA US Bioassay | Virtual Conference | March 22 - 25 Meet with Catalent at BEBPA US Bioassay Conference.
BIO-Europe Spring Digital | Virtual Conference | March 22 - 25 Meet with Catalent at BIO-Europe Spring.
Webinar | Utilizing GPEx® Cell Line Development for Difficult-to-Express Proteins | March 23 Greg Bleck, Ph.D., Vice President, R&D, Catalent Biologics, will discuss new cell line development methodologies that are enabling complex biopharmaceutical programs to be performed more efficiently, and a new approach to generate stable pooled cell lines.
|
|
|
|
|
| |
| |
| |
| |
| A Catalyst in Drug Development | | Mubashar Chughtai Associate Senior Scientist, Ontario, Canada |
|
|
|
|
| An active member of Catalent’s scientific research community, Mr. Chughtai has over 11 years of experience as a Bioinorganic Chemist. He is heavily involved in method validations and verifications and has worked on the transfer of complex residual solvents including USP<467> methods. Mr. Chughtai is based at Catalent’s facility in Windsor, Ontario, and thrives on meeting challenges head on and facing them with sound scientific principles. |
|
| | |
|
|
| |
| |
| |
| |
| Cell & Gene Therapy
Webinar: “Are Real-Time Gene Therapy Test Results Possible?” - Learn more about label-free analysis providing near real-time infectivity measurements and timely, cost-effective measurements helping process optimization and scale-up. Webinar: “Manufacturing Innovation Across New Modalities” - In this talk, Catalent experts present key areas of technology innovation that have the potential to reshape how advanced therapeutics are manufactured at scale. Webinar: “Navigating the Path to the Clinic and Beyond for Gene Therapies” - A gene therapy’s path from the research lab to the clinic and ultimately the market requires manufacturing processes that will meet regulatory requirements and the logistics to get therapies to clinical trial sites. In this webinar, Catalent experts discuss navigating the path. |
|
|
|
|
| |
| |
| |
| We are the Catalyst for your Success. Join Us! |
|
|
|
|
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana; Madison, Wisconsin; Harmans, Maryland; Kansas City, Missouri; and more.
Visit www.catalent.com/careers for more information. |
|
|
|
|
| |
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at [email protected], or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
| |
